US/EU AI MedTech Split: Pure Global on Hidden Hurdles

The promise of AI in medical devices is immense, but new guidance from US and European authorities reveals a widening gap in regulatory expectations. This episode of MedTech Global Insights breaks down the critical differences in how the FDA and EU handle AI device updates and what this means for your global strategy. We explore the practical impact of the FDA's flexible framework versus the EU's more rigid requirements under the MDR and AI Act. For innovators, this divergence creates major challenges for product development, timelines, and budgets, potentially slowing the delivery of life-saving technology to patients. **Case In Point:** Imagine developing a self-improving diagnostic algorithm. In the US, you can update it rapidly. But in the EU, each update could mean a costly and slow re-certification. How do you launch a single, competitive product globally without doubling your regulatory workload and creating major delays? **Key questions we explore in this episode:** - What are the core differences between the new FDA and EU guidance on AI/ML devices? - How does the FDA's "Predetermined Change Control Plan" offer a competitive advantage? - Why might the EU's approach stifle rapid innovation for AI-driven MedTech? - What are the strategic risks of developing a single AI software for both markets? - How can you build a technical dossier that efficiently satisfies both US and EU requirements? - What post-market data is critical for maintaining compliance in Europe? - For a startup, which market offers a faster entry point for an AI device? Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.